Study of a new drug for acute migraine attacks
Part of Brain & nervous system clinical trials.
This study tests an investigational medication called NB001 for treating migraine attacks as they happen. If you have frequent migraines, this treatment might help reduce the severity or shorten the duration of your attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a doctor's diagnosis of migraine (with or without aura).
- You have had migraines for at least 1 year, and they started before age 50.
- You have 2 to 8 moderate or severe migraine attacks per month.
- Your untreated migraines usually last 4 to 72 hours.
- You can use a smartphone app or tablet to record your symptoms.
- You are willing to use contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new ways to monitor how well preventive migraine treatments are working. It is for people with chronic migraine who may be starting or already using preventive medications.
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
This trial tests a substance that activates adrenomedullin receptors, which may be a new way to treat migraines. It may help people who have migraines without aura and aren't on preventive migraine medications.
This trial tests if a gentle nasal stimulation device can help prevent migraines. It is for adults with frequent migraines (at least 8 days per month).
This trial tests whether an oral capsule called butylphthalide (also known as NBP) can help prevent migraine attacks in adults who get them regularly. If you have migraines 4–14 days per month, this study may offer a new preventive option.
This study tests a new inhaled powder form of a migraine medication called dihydroergotamine (DHE) to see if it safely and effectively stops migraine attacks. If you have frequent migraines, this trial might offer you a new treatment option to try.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.